Galactoarabino-rhamnogalacturonate: Additional Phase I data

Data from 9 NASH patients with advanced liver fibrosis in the third cohort of the double-blind, placebo-controlled, dose-escalation, U.S. Phase I GT-020 trial showed that infusions of 8 mg/kg IV GR-MD...